Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
Journal for ImmunoTherapy of Cancer · 2025
DOI: 10.1136/jitc-2024-010132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Johnathan Arnon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel arnony@hadassah.org.il gal@pangeabiomed.com. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Adenocarcinoma of Lung, Lung Neoplasms, Transcriptome. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Immune checkpoint inhibitors (ICI) have improved outcomes in non-small cell lung cancer (NSCLC). Nevertheless, the clinical benefit of ICI as monotherapy or in combination with chemotherapy remains widely varied and existing biomarkers have limited predictive value. We present an analysis of ENLIGHT-DP, a novel transcriptome-based biomarker directly from histopathology slides, in patients with lung adenocarcinoma (LUAD) treated with ICI and platinum-based chemotherapy.
Methods
We retrospectively scanned high-resolution H&E slides from pretreatment tumor-tissue samples of 50 patients with metastatic LUAD treated with first-line ICI with (46) or without (4) platinum-based chemotherapy and applied our ENLIGHT-DP pipeline to generate, in a blinded manner, an individual prediction score. ENLIGHT-DP predicts response to ICI and targeted therapies given H&E slide scans in two steps: (1) predict individual messenger RNA expression directly from high-resolution H&E scanned slides using DeepPT, a digital-pathology-based algorithm. (2) Use these values as input to ENLIGHT, a transcriptome-based platform that predicts response to ICI and targeted therapies derived from drug-specific networks of gene expressions. We then unblinded the clinical outcomes and evaluated the predictive value of ENLIGHT-DP in comparison to programmed death ligand (PD-L)-1 and tumor mutational burden (TMB).
Results
ENLIGHT-DP is predictive of response to treatment with receiver operating characteristic (ROC) area under the curve (AUC) of 0.69 (p=0.01) and outperforms both TMB and PD-L1 expression with ROC AUC of 0.52 and 0.46, respectively. Using a predetermined binary cut-off (established on independent cohorts) for patients predicted to respond to ICI, ENLIGHT-DP achieves 100% positive predictive value (PPV) and 44% sensitivity, superior to both PD-L1>50% (65% PPV and 38% sensitivity) and TMB-high (82% PPV and 26% sensitivity). ENLIGHT-DP was highly predictive in PD-L1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel arnony@hadassah.org.il gal@pangeabiomed.com.
- Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Pangea Biomed, Tel Aviv, Israel arnony@hadassah.org.il gal@pangeabiomed.com.
- Pangea Biomed, Tel Aviv, Israel.
- Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
- Sharett Institue of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Zitieren
APA
Arnon, J., Dinstag, G., Tirosh, O., Gugel, L., Kinar, Y., Gottlieb, T., Elia, A., Rottenberg, Y., Nechushtan, H., Tabi, M., Blumenfeld, P., Pikarsky, E., Beker, T., Aharonov, R., & Popovtzer, A. (2025). Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010132
Vancouver
Arnon J, Dinstag G, Tirosh O, Gugel L, Kinar Y, Gottlieb T, et al. Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2024-010132
BibTeX
@article{Arnon2025,
author = {Arnon, Johnathan and Dinstag, Gal and Tirosh, Omer and Gugel, Leon and Kinar, Yaron and Gottlieb, Tzivia and Elia, Anna and Rottenberg, Yakir and Nechushtan, Hovav and Tabi, Michael and Blumenfeld, Philip and Pikarsky, Eli and Beker, Tuvik and Aharonov, Ranit and Popovtzer, Aron},
title = {Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
doi = {10.1136/jitc-2024-010132}
}
EUVIMED